Literature DB >> 24633461

[Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].

T Lapp1, P Maier, F Birnbaum, G Schlunck, T Reinhard.   

Abstract

In order to prevent rejection of an allogeneic corneal transplant after perforating (high risk) keratoplasty, active agents from different classes of pharmacological substances are used, as with solid organ transplantation. In addition to glucocorticoids, antiproliferative agents, small molecule inhibitors and antibodies, those belonging to the group of macrolides with their many derivatives represent an interesting class of substances in this context. As a supplement to cyclosporin A (CSA) the most successful macrolide in transplantation medicine, animal experiments are currently being carried out to test newer macrolide derivatives, such as sanglifehrin A (SFA). This overview describes the classes of drugs and modes of action of currently administered standard medications in the clinical routine and new developments are presented.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633461     DOI: 10.1007/s00347-013-3016-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  103 in total

Review 1.  [Systemic immunosuppressives after penetrating keratoplasty].

Authors:  A Reis; F Birnbaum; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

2.  Total Synthesis of Sanglifehrin A.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  1999-08       Impact factor: 15.336

Review 3.  CXCL10: a candidate biomarker in transplantation.

Authors:  Paola Romagnani; Clara Crescioli
Journal:  Clin Chim Acta       Date:  2012-02-16       Impact factor: 3.786

4.  A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.

Authors:  C Brattström; G Tydén; J Säwe; G Herlenius; K Claesson; C G Groth
Journal:  Transplant Proc       Date:  1996-04       Impact factor: 1.066

5.  Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53.

Authors:  L H Zhang; H D Youn; J O Liu
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

Review 6.  Steroids.

Authors:  Maggy Riad; Marianna Mogos; Duraiyah Thangathurai; Philip D Lumb
Journal:  Curr Opin Crit Care       Date:  2002-08       Impact factor: 3.687

Review 7.  Overview of safety of non-biologic and biologic DMARDs.

Authors:  Eric M Ruderman
Journal:  Rheumatology (Oxford)       Date:  2012-12       Impact factor: 7.580

8.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group.

Authors:  M G Maguire; W J Stark; J D Gottsch; R D Stulting; A Sugar; N E Fink; A Schwartz
Journal:  Ophthalmology       Date:  1994-09       Impact factor: 12.079

Review 9.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

10.  Long term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.

Authors:  Florian Birnbaum; Alexander Reis; Thomas Reinhard
Journal:  Cornea       Date:  2009-07       Impact factor: 2.651

View more
  1 in total

Review 1.  [Current treatment options with artificial corneas: Boston Kpro, Osteo-odontokeratoprosthesis, Miro Cornea® and KeraKlear®].

Authors:  N Schrage; K Hille; C Cursiefen
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.